Improvement of quality of life in patients with concomitant allergic asthma and atopic dermatitis: one year follow-up of omalizumab therapy by Velling, P et al.
407 September 12, 2011 Eu  Ro  PE  an JouR  nal of MED  I  Cal RE  SEaRCH
Abstract
Objective: anti IgE treatment with omalizumab is effi-
cacious in the treatment of patients suffering from al-
lergic asthma, improving asthma control and improv-
ing quality of life. furthermore, this approach could
be beneficial for patients with concomitant atopic der-
matitis. we assessed quality of life and asthma control
in atopic patients with allergic asthma and concomi-
tant atopic dermatitis versus those with asthma and
without atopic dermatitis treated with omalizumab.
Methods: a  total  of  22  patients  with  severe  allergic
asthma were treated with omalizumab for 12 months.
13 patients with allergic asthma without concomitant
atopic dermatitis (IgE 212 ﾱ 224 Iu/ml) and 9 pa-
tients with concomitant allergic asthma and atopic der-
matitis  (IgE  3,528  ﾱ  2,723  Iu/ml)  were  included.
asthma-related  quality  of  life  (aQlQ),  atopic  der-
matitis related quality of life (DlQI), and asthma-re-
lated treatment were compared between both groups
at baseline and after initiating omalizumab treatment.
Results: DlQI was significantly in favor of omalizum-
ab  after  2  months  in  the  atopic  dermatitis/asthma
group (P = 0.01); aQlQ was improved after 6 months
in the asthma group (P = 0.01), while no change was
seen in aQlQ in the atopic dermatitis/asthma group
(P = 0.12). omalizumab controlled oral corticosteroid
use  more  effective  (P<0.01)  in  patients  with  asthma
and atopic dermatitis (in 9/9 cases) compared to pa-
tients with asthma alone (9/13). baseline IgE as well as
other factors do not predict response to omalizumab.
Conclusions:  omalizumab  is  effective  in  improving
atopic  dermatitis-related  quality  of  life  scores  and
modulates oral corticosteroid use in patients with con-
comitant  asthma  and  atopic  dermatitis  in  a  positive
fashion.
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IntRoDuCtIon
atopic dermatitis is a chronic cutaneous inflammato-
ry disease in childhood that often persists into adult-
hood  [2].  It  is  characterized  by  pruritic  skin 
lesions and frequently associated with allergic asthma
disease, and atopic diathesis, or both. the syndrome
of  atopy  may  include  allergic  rhino  conjunctivitis, 
allergic  asthma,  and  atopic  dermatitis;  most  cases 
of  moderate  to  severe  atopic  dermatitis  do  not 
respond adequate to any single therapeutic modality
and many management strategies based on systemic
or local corticosteroids are limited by their systemic
toxicities. Currently, we do not have effective pharma-
cological monotherapies with acceptable safety pro-
files to control the symptoms of this disease in the
long run. 
omalizumab  is  an  anti-immunoglobulin  E  (IgE)
monoclonal antibody for use in IgE-mediated allergic
asthma. the efficacy of omalizumab has been exten-
sively evaluated in several clinical studies in patients
with  predominantly  severe  persistent  allergic  asthma
[3, 5, 6, 11]. omalizumab has proven effective over a
wide range of outcome measures including asthma ex-
acerbation rates, total emergency visit rates, and quali-
ty of life (Qol). both diseases – asthma and atopic
dermatitis – are associated with elevated serum IgE
levels,  that  are  strongly  increased  in  patients  with
atopic dermatitis. Indeed, omalizumab has been exper-
imentally used in various atopic skin diseases including
atopic  dermatitis  with  high  IgE  levels.  Efficacy  of
omalizumab in atopic skin diseases is heterogeneous
and ranges from very good efficacy to no effect at all
in case reports and small studies [7, 8, 9, 13, 14]. How-
ever, no data exist on the evaluation of omalizumab
treatment in patients with both atopic dermatitis and
asthma.
the aim of the present study was to evaluate the ef-
ficacy and safety of omalizumab in patients with con-
comitant  asthma  and  atopic  dermatitis  versus  those
with asthma alone. In particular, we were interested in
changes of quality of life and asthma control.
MEtHoDS
In a prospective monocenter investigation we assessed
a series of 22 atopic patients with omalizumab therapy
for 12 months starting between July 2006 and october
2008. Inclusion criteria for all patients were identical
to  that  of  the  InnoVatE  study  [6,  12]  -  except
serum IgE levels (≥30 to ≤700 Iu/ml). Inclusion cri-
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patients with persistent allergic asthma (12–75 years):
Positive skin prick test to ≥1 perennial aeroallergen, to
which they were likely to be exposed during the study,
severe  persistent  asthma  requiring  regular  treatment
with  >1000  ﾵg/day  beclomethason  dipropionate  or
equivalent and long-acting β2-agonist (global Initia-
tive for asthma (gIna) step 4 treatment), forced ex-
piratory volume in 1 s (fEV1) ≥40 to <80% of pre-
dicted normal value and continuing asthma symptoms,
fEV1 reversibility ≥12% from baseline within 30 min
of inhaled (up to 400 ﾵg) or nebulized (up to 5 mg)
salbutamol, despite high-dose ICS and laba use at
least two asthma exacerbations requiring systemic cor-
ticosteroids, or one severe exacerbation [peak expira-
tory  flow  (PEf)/fEV1  <60%  of  personal  best,  re-
quiring systemic corticosteroids] resulting in hospital-
ization or emergency room treatment, in the past 12
months. thirteen patients with allergic asthma served
as controls, and 9 patients with concomitant allergic
asthma and atopic dermatitis were included. Patients
with allergic asthma alone had a mean fEV1 of 71%
of  predicted,  patients  with  concomitant  atopic  der-
matitis of 76% (table 1).
whereas total serum IgE levels were >30 to <700
Iu/ml (mean 212 ﾱ 224 Iu/ml) in patients with asth-
ma  alone,  all  patients  with  concomitant  atopic  der-
matitis  displayed  total  serum  IgE  values  above  700
Iu/ml  (mean  3,528  ﾱ  2,723  Iu/ml).  the  dose  of
omalizumab  (Xolair,  novartis,  n￼rnberg,  germany)
was dependent on body weight and serum IgE levels
and was administered every 2 or 4 weeks, as described
[3,  6].  Patients  with  concomitant  atopic  dermatitis
were treated regardless of IgE values with 150 mg s.c.
in 14 day intervals based on the observation of previ-
ous work [1, 10]. omalizumab dosage was increased
up to a improvement of dermatological status; dosage
did not exceed the maximal two week-dosage of 450
mg s.c. asthma-related quality of life (aQlQ), atopic
dermatitis related quality of life (DlQI) [4], and treat-
ment with oral steroids were compared between both
groups at baseline and 1, 2, 3, 6 and 12 months after
initiating omalizumab treatment. adverse events were
recorded at each treatment visit. 5 additional patients
with asthma alone were excluded from study analysis
due to anaphylactic reaction after first omalizumab in-
jection (n = 1) or discontinuation of therapy due to
unsatisfactory  therapeutic  effect  on  asthma  despite
correct dosage within the first six months (n = 4).
StatIStICal analySIS
Probability was calculated with the students t-test; P
values of <0.05 were considered to be statistically sig-
nificant. all studies have been carried out according to
the Helsinki declaration of good clinical practice.
RESultS
Patient characteristics, such as age, gender, and med-
ication did not differ between patients with asthma (n
=  13)  and  patients  with  concomitant  asthma  and
atopic dermatitis (n = 9) and are presented in table 1.
all  patients  were  receiving  inhaled  corticosteroids
(>1000 ﾵg/day beclomethason dipropionate or equiv-
alent) and long-acting β2-agonists (fixed combination
of  fluticason/salmeterol  or  budesonid/formeterol),
12/13  of  patients  with  asthma  and  7/9  of  patients
with  asthma/atopic  dermatitis  received  additional
maintenance  oral  corticosteroid  at  baseline.  Consis-
tently,  patients  with  asthma  and  atopic  dermatitis
showed significantly higher serum IgE values than pa-
tients with asthma alone (3,528 ﾱ 2,723 Iu/ml vs. 212
ﾱ 224 Iu/ml, P<0.001). of note, there was no signifi-
cant  difference  between  both  groups  regarding  the
omalizumab dosage.
aQlQ was improved for the total collective (P =
0.01) and in the asthma alone group after 6 months (P
= 0.01), while no change was seen in aQlQ in the
atopic  dermatitis/asthma  group  (P  =  0.12)  (fig.  1).
there  were  no  significant  changes  at  earlier  time
points. DlQI was significantly in favor of omalizum-
ab  after  2  months  in  the  asthma/atopic  dermatitis
group (P = 0.01); this effect was seen until 12 months
(fig.  2).  overall  improvements  in  DlQI  indices  as
well  as  in  minimizing  topic  corticosteroids  in  skin
therapy were found in all patients with asthma/atopic
dermatitis. During treatment, both patient groups low-
ered  their  use  of  oral  corticosteroids:  all  (9/9)  pa-
tients with asthma/atopic dermatitis discontinued oral
corticosteroid use, whereas 9/13 patients with asthma
alone stopped this therapy. 
baseline IgE, age, body weight, fEV1 and dosage
of omalizumab do not predict response to omalizum-
ab.
overall,  4  of  the  22  patients  having  received  12
months  omalizumab  (18%)  experienced  at  least  one
adverse effect: headache (n = 1), local reaction at point
of injection (n = 4) and nausea (n = 1). 
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Table 1. Patient characteristics, asthma-related quality of life
(aQlQ), atopic dermatitis related quality of life (DlQI), and
asthma-related  treatment  at  baseline  and  after  6  and  12
months omalizumab therapy. oCS, oral corticosteroids, ICS,
inhaled corticosteroids.
asthma asthma +  P value 
atopic dermatitis
n 13 9
age (years) 47.5 ﾱ14.8 38.1 ﾱ 11.3 0.127
Sex /female) 10/13  77% 6/9  67% 0.394
IgE 212 ﾱ 224 3528 ﾱ 2723 < 0.001
fEV1 71.5 ﾱ 10,7 76.2 ﾱ 7,4 0.350
weight in kg 82.3 ﾱ 22.0 76.3 ﾱ 16.1 0.472
omalizumabdosage
(mg/2 weeks) 213 ﾱ 86 233 ﾱ 109 0.654
oCS baseline 12/13 7/9 0.394
oCS 6 month 4/13 0/9 0.003
oCS 12 month 4/13 0/9 0.003
aQlQ baseline 102 ﾱ 40 143 ﾱ 44 0.041
aQlQ 6 month 148 ﾱ 48 175 ﾱ 40 0.041
aQlQ 12 month 152ﾱ 45 170ﾱ 42 0.04
DlQI baseline 19 ﾱ 10
DlQI 6 month 7 ﾱ 8
DlQI 12 moth 6 ﾱ 6
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the present study is the first designed to evaluate the
efficacy of omalizumab on quality of life (Qol) in pa-
tients with concomitant asthma and atopic dermatitis.
omalizumab is effective in improving atopic dermati-
tis-related  Qol  scores  and  modulates  oral  corticos-
teroid  treatment.  all  patients  had  severe  persistent
asthma  as  defined  by  global  Initiative  for  asthma
(gIna) guidelines [12]. omalizumab was used as an
add-on  treatment  to  standard  management.  Indeed,
improvement in asthma Qol in the groups was similar
and comparable to other reports with omalizumab [3,
6]. In addition, in the comorbid population suffering
from  atopic  dermatitis  and  asthma,  treatment  with
omalizumab  resulted  in  significant  improvements  of
atopic dermatitis-related Qol and in reduction of use
of oral corticosteroids. Choice of the long-term ob-
servational  interval  (>12months)  was  based  on  the
possibility and variability of placebo-induced clinical
improvement in atopic dermatitis. this phenomenon
was described in the first three months of observation
period in up to 40% of the cases after initiation of a
new  treatment  option  [1].  of  interest,  changes  in
atopic dermatitis-related Qol were seen 2 months af-
ter initiating omalizumab treatment, whereas improved
asthma Qol reached significance only after 6 months.
of note, the present improvement of Qol scores
in  patients  with  concomitant  atopic  dermatitis  and
asthma  was  observed  with  low-dose  anti  IgE  treat-
ment (233 ﾱ 109 mg/2 weeks) and, therefore, was in a
much lower dosage than required for the complete re-
moval of IgE from the circulation, as recently also de-
scribed by lim and belloni [1, 10]. they had observed
free IgE remained basically stable over the omalizum-
ab treatment period and suggested other, molecular ef-
fects such as a switch to reduced IgE mRna produc-
tion  responsible  for  skin  improvement  [1,  10].  one
may speculate, that those patients with lower IgE lev-
els would show a better Qol improvement, however,
this is not shown by the present data. Indeed, mean
IgE level 3,528 ﾱ 2,723 Iu/ml in the present study is
even  higher  than  in  previous  studies,  for  example
1,521 Iu/ml in the work of Sheinkopf and colleagues
[13].
there  are  several  limitations  of  this  single-center
project with a small study collective that was designed
as a pilot study, not as a randomized trial. the concept
that underlies this study was the screening of the im-
pact on quality of life brought on by omalizumab de-
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Fig.  1.  time course of aQlQ for pa-
tients with asthma alone (red) and con-
comitant  atopic  dermatitis  and  asthma
(blue). aQlQ was improved in the asth-
ma  alone  group  after  6  months  omal-
izumab treatment (P<0.05: 2 months, 3
months,  6  months  and  12  months  vs.
baseline),  while  no  significant  change
was seen in aQlQ in the atopic dermati-
tis/asthma group.
Fig.  2.  time course of DlQI that was
significantly  in  favor  of  omalizumab
treatment in the atopic dermatitis/asth-
ma group (P<0.05: 2 months, 3 months,
6 months and 12 months vs. baseline).
atopic dermatitis
atopic dermatitis
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scription  in  patients  with  atopic  disease,  as  seen  in
“daily practice”.
In  conclusion,  this  study  extends  previously  pub-
lished reports on omalizumab in atopic dermatitis [1,
10, 13] by integrating patients with concomitant asth-
ma and atopic dermatitis and found that omalizumab
is significantly efficacious in improving disease-related
Qol when added to standard asthma and atopic der-
matitis therapies. further placebo-controlled studies in
this patient collective are warranted. 
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